US 9453220
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
granted A61KA61K31/7088
Quick answer
US patent 9453220 (RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders) held by Arrowhead Pharmaceuticals, Inc. expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K31/7088